BetterLife Pharma Inc.

Equities

BETRF

CA08772P2026

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:22:24 2024-04-30 am EDT			5-day change	1st Jan Change
0.0751 ^USD	-0.27%		+4.45%	+56.46%

Apr. 03	BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding	CI
Mar. 04	BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding	CI

BetterLife Pharma Inc. announced that it has received CAD 0.15 million in funding

March 13, 2023

On March 14, 2023, BetterLife Pharma Inc. closed the transaction. The company has issued 1,500,000 units at a price of CAD 0.10 per unit for aggregate gross proceeds of CAD 150,000. The transaction included participation from Doroudian for 2,000,000 units for CAD 200,000.

Latest news about BetterLife Pharma Inc.

BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding	Apr. 02	CI
BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding	Mar. 03	CI
BetterLife Pharma Inc. announced that it has received CAD 0.065 million in funding	Mar. 03	CI
BetterLife Closes Convertible Debentures For Further Development of BETR-001	Jan. 02	MT
BetterLife Pharma Inc. announced that it has received CAD 0.3 million in funding	Jan. 01	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 29	CI
BetterLife Pharma Inc. announced that it has received CAD 0.2 million in funding	Dec. 17	CI
Us Patent and Trademark Office Publishes Betterlife?S Comprehensive Patent for Betr-001 and Other Lsd Derivatives	Nov. 30	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-27	CI
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001	23-09-12	CI
BetterLife Pharma Inc. announced that it has received CAD 0.295 million in funding	23-08-30	CI
BetterLife Pharma Inc. announced that it has received CAD 0.22 million in funding	23-07-12	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-28	CI
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives	23-06-27	CI
BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development Advisor	23-06-22	CI
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies	23-06-08	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
BetterLife Pharma Inc. Auditor Raises 'Going Concern' Doubt	23-05-30	CI
BetterLife Pharma Inc. to Present BETR-001 Preclinical Data At the 2023 Annual Meeting of the Society of Biological Psychiatry in San Diego, California	23-04-25	CI
BetterLife Pharma Raises $1.9 Million via Private Placement	23-03-14	MT
BetterLife Pharma Raises $1.9 Million via Private Placement	23-03-14	MT
BetterLife Pharma Inc. announced that it has received CAD 0.357143 million in funding	23-03-13	CI
BetterLife Pharma Inc. announced that it has received CAD 0.15 million in funding	23-03-13	CI
BetterLife Pharma Inc. Publishes Promising Results from Study Titled "A Non-Hallucinogenic LSD Analog with Therapeutic Potential for Mood Disorders	23-03-09	CI
BetterLife Pharma Prices Private Placement Offering	23-03-08	MT

Chart BetterLife Pharma Inc.

Duration

Period

More charts

Company Profile

BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Companyâs subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BETTERLIFE PHARMA INC.	+56.46%	8.74M
VERTEX PHARMACEUTICALS INCORPORATED	-3.19%	102B
REGENERON PHARMACEUTICALS, INC.	+1.56%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.61%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-15.66%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.06%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.27%	12.17B

Bio Therapeutic Drugs